| S1R Stock | | | EUR 1.49 0.02 1.36% |
President
Bo Shen is Chief Financial Officer, Vice President, Executive Director of Shanghai Pharmaceuticals Holding since 2016.
| Age | 50 |
| Tenure | 8 years |
| Phone | 86 21 6373 0908 |
| Web | https://www.sphchina.com |
Shanghai Pharmaceuticals Management Efficiency
The company has return on total asset
(ROA) of
0.0281 % which means that it generated a profit of $0.0281 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity
(ROE) of
0.1024 %, meaning that it generated $0.1024 on every $100 dollars invested by stockholders. Shanghai Pharmaceuticals' management efficiency ratios could be used to measure how well Shanghai Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities.
Shanghai Pharmaceuticals Holding has accumulated 7.16
B in total debt with debt to equity ratio
(D/E) of 0.67, which is about average as compared to similar companies. Shanghai Pharmaceuticals has a current ratio of 1.21, suggesting that it
may have difficulties to pay its financial obligations in time and when they become due. Debt can assist Shanghai Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Shanghai Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Shanghai Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Shanghai to invest in growth at high rates of return. When we think about Shanghai Pharmaceuticals' use of debt, we should always consider it together with cash and equity.
Similar Executives
Shanghai Pharmaceuticals Holding Co., Ltd., an investment holding company, researches, develops, manufactures, distributes, and retails pharmaceutical and healthcare products in the Peoples Republic of China. Shanghai Pharmaceuticals Holding Co., Ltd. is a subsidiary of Shanghai Pharmaceutical Co., Ltd. SHANGHAI PHARM operates under Medical Distribution classification in Germany and is traded on Frankfurt Stock Exchange. It employs 46609 people. Shanghai Pharmaceuticals Holding (S1R) is traded on Frankfurt Exchange in Germany and employs 47,056 people.
Management Performance
Shanghai Pharmaceuticals Leadership Team
Elected by the shareholders, the Shanghai Pharmaceuticals' board of directors comprises two types of representatives: Shanghai Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Shanghai. The board's role is to monitor Shanghai Pharmaceuticals' management team and ensure that shareholders' interests are well served. Shanghai Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Shanghai Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Jun Zhou, Chairman of the Board, Non-Executive Director | |
| Dawei Liu, Vice President Secretary of the Board | |
| Haoliang Gu, Vice President | |
| Liang Hong, Independent Non-Executive Director | |
| Ying Ke, Director Center | |
| Yong Zhao, Vice President | |
| Tao Zhong, Board VP | |
| Jiangnan Cai, Independent Non-Executive Director | |
| Man Cho, Pres Director | |
| Shunjiang Yu, Chief Officer | |
| Jianyi Mao, Vice President | |
| Min Zuo, President Executive Director | |
| Yaohua Zhang, Vice President | |
| Chaoyang Gu, Independent Non-Executive Director | |
| Yongzhong Li, Vice President Executive Director | |
| Jinzhu Chen, Secretary of the Board | |
| Wenxun Huo, Independent Non-Executive Director | |
| An Li, Non-Executive Director | |
| Jinqi Yu, G Mang | |
| Dawei Ge, Vice Chairman of the Board, Non-Executive Director | |
| Shui ACS, Joint Sec | |
| Bo Shen, Chief Financial Officer, Vice President, Executive Director | |
| Linqiong Dong, Securities Representative | |
Shanghai Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Shanghai Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Currently Active Assets on Macroaxis
Other Information on Investing in Shanghai Stock
Shanghai Pharmaceuticals financial ratios help investors to determine whether Shanghai Stock is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Shanghai with respect to the benefits of owning Shanghai Pharmaceuticals security.